| Identification | Back Directory | [Name]
CKD-519 | [CAS]
1402796-27-3 | [Synonyms]
CKD-519
Rocacetrapib
CKD519,CKD 519
2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-[4-fluoro-2-methoxy-5-(1-methylethyl)phenyl]-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-4-methyl-, (4S,5R)- | [Molecular Formula]
C31H34F7NO3 | [MDL Number]
MFCD28502128 | [MOL File]
1402796-27-3.mol | [Molecular Weight]
601.6 |
| Hazard Information | Back Directory | [Uses]
CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an IC50 of 2.3 nM[1]. | [References]
[1] Kim CO, et al. Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects. Drug Des Devel Ther. 2016 Nov 15;10:3763-3770. DOI:10.2147/DDDT.S120387 |
|
|